Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BMLBMLKF 73 Earnings Yield (Joel Greenblatt) % is 13.04% as of Mar. 2026, which is 8% below its 10-year median of 14.10. GuruFocus rates BMLKF with a GF Score™ of 73/100 and a GF Value™ of $27.14. The stock has 2 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, BML ranks better than 95.31% on this metric.
BML's Enterprise Value for the quarter that ended in Mar. 2026 was $574.6 Mil.
BML's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $80.2 Mil. BML's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 13.04%.
The historical rank and industry rank for BML's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
BMLKF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.02 Med: 14.1 Max: 120.46
Current: 16.26
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of BML was 120.46%. The lowest was 6.02%. And the median was 14.10%.
BMLKF's Earnings Yield (Joel Greenblatt) % is ranked better than 95.31% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.41
vs BMLKF: 16.26
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. BML's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was -6.31%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
BML Earnings Yield (Joel Greenblatt) % Related Terms
BML Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for BML's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BML's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BML Earnings Yield (Joel Greenblatt) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BML's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where BML's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
BMLs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Mar. 2026 is calculated as
BML's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $80.2 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 13.04% mean?
BML (BMLKF) has a Earnings Yield (Joel Greenblatt) % of 13.04% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on BML and its competitors. This is near median its historical median of 14.10. Over the past decade, BML's Earnings Yield (Joel Greenblatt) % has ranged from 6.02 to 120.46. According to the industry distribution chart, BML ranks #10 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 4.7%.
Is BML's Earnings Yield (Joel Greenblatt) % too high?
BML's current Earnings Yield (Joel Greenblatt) % of 13.04% is near median its 10-year median of 14.10. Over the past 10 years, this metric has ranged from a low of 6.02 to a high of 120.46. Based on the distribution chart, BML ranks #10 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, BML has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does BML's Earnings Yield (Joel Greenblatt) % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BML ranks #10 out of 213 companies for Earnings Yield (Joel Greenblatt) %. This places BML in the top 5% of its industry — outperforming the majority of peers. Historically, BML's own Earnings Yield (Joel Greenblatt) % has ranged from 6.02 to 120.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Diagnostics & Research company?
A good Earnings Yield (Joel Greenblatt) % depends on the Medical Diagnostics & Research industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on BML and its competitors. BML's current Earnings Yield (Joel Greenblatt) % is 13.04%, which is near median its own 10-year median of 14.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BML stock overvalued right now?
BML (BMLKF) has a current Earnings Yield (Joel Greenblatt) % of 13.04%. The stock's GF Value™ is $27.14, compared to a current price of $25.21 — trading 7.1% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 13.04%, which is near median its 10-year median of 14.10. BML's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For BML (BMLKF), the current Earnings Yield (Joel Greenblatt) % is 13.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BML (BMLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BML stock appears to be undervalued.
The current stock price of $25.21 is trading 7.1% below its estimated GF Value™ of $27.14.
Key valuation signals for BMLKF:
Earnings Yield (Joel Greenblatt) %: 13.04% (near median its 10-year median of 14.10)
GF Value™: $27.14 vs. price of $25.21 (7.1% below fair value)
No single metric tells the full story. See the BMLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.
73GF Score
Get the complete analysis for BMLKF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMLKF has been successfully added to your 
